A Phase 1b Trial of LY2584702 in Combination With Erlotinib or Everolimus in Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2014
At a glance
- Drugs LY 2584702 (Primary) ; Erlotinib; Everolimus
- Indications Cancer; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Renal cell carcinoma
- Focus Adverse reactions
- 06 Jan 2012 Planned End Date changed from 1 Jul 2013 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 21 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Sep 2011 Planned end date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.